Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Kabi, Mylan and Neptune Thwarted In US Pemetrexed Proceedings
May 01 2019
•
By
Aidan Fry
A US Court of Appeals ruling has halted potential generics of Lilly's Alimta pemetrexed brand until 2022 • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin
